J. Bryant

发表

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

M. Cronin, S. Paik, G. Tang, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

Anna L. Brown, J. Bryant, D. Wickerham, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.

J. Bryant, N. Wolmark, E. Mamounas, 2001, Journal of the National Cancer Institute. Monographs.

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

M. Cronin, S. Paik, G. Tang, 2004, The New England journal of medicine.

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials

J. Bryant, N. Wolmark, B. Fisher, 2004, The Lancet.

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.

Norman Wolmark, James J Dignam, Soonmyung Paik, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Greg Yothers, Peter A Kaufman, Norman Wolmark, 2005, The New England journal of medicine.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.

J. Bryant, N. Wolmark, B. Fisher, 2002, Cancer.

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.

B Fisher, J. Bryant, D. Wickerham, 1997, Journal of the National Cancer Institute.

Design and Analysis of Oncology Clinical Trials

J. Bryant, J. Dignam, T. Karrison, 2006 .

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.

S. Paik, J. Bryant, D. Wickerham, 2000, Journal of the National Cancer Institute.

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

Greg Yothers, Norman Wolmark, Soonmyung Paik, 2002, Journal of the National Cancer Institute.

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

B Fisher, J Costantino, C. Redmond, 1996, Journal of the National Cancer Institute.

Duration of adjuvant tamoxifen therapy.

J. Bryant, B. Fisher, J. Dignam, 2001, Journal of the National Cancer Institute. Monographs.

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Terry L. Smith, R. Collins, L. Holmberg, 1998, Lancet.

American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.

E. Winer, S. Edge, T. Powles, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Natural killer cytotoxicity in the diagnosis of immune dysfunction: Criteria for a reproducible assay

R. Day, J. Bryant, T. Whiteside, 1990, Journal of clinical laboratory analysis.

Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen.

W. McCaskill-Stevens, J. Bryant, D. Wickerham, 2004, Journal of the National Cancer Institute.

Letrozole after tamoxifen for breast cancer--what is the price of success?

J. Bryant, N. Wolmark, 2003, The New England journal of medicine.

What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting?

J. Bryant, 2004, Statistics in medicine.

Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.

Jong-Hyeon Jeong, Norman Wolmark, J. Bryant, 2002, The New England journal of medicine.

Association of tamoxifen and uterine sarcoma.

J. Bryant, J. Costantino, D. Wickerham, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Re: Risk/benefit assessment of tamoxifen to prevent breast cancer-still a work in progress?

R. Croyle, M. Gail, J. Bryant, 2000, Journal of the National Cancer Institute.

Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient.

P. Brown, M. Mehta, J. Buatti, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Mike Clarke, Yasuo Ohashi, Michael Gnant, 2018, The Lancet. Oncology.

Gene Therapy of Cancer: A Pilot Study of IL-4-Gene-Modified Fibroblasts Admixed with Autologous Tumor to Elicit an Immune Response. University of Pittsburgh

J. Kirkwood, J. Bryant, T. Whiteside, 1994 .

Radiotherapy review on national surgical adjuvant breast and bowel project (NSABP) phase III breast cancer clinical trials: is there a need for submission of portal/simulation films?

J. Bryant, M. Deutsch, G. Bass, 1999, American journal of clinical oncology.

Pattern of loco-regional and distant failure in patients with breast cancer treated with mastectomy and chemotherapy (+/- Tamoxifen) without radiation: results from five NSABP randomized trials

A. Taghian, J. Bryant, E. Mamounas, 2001 .

Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.

C. Snyderman, J. Johnson, J. Bryant, 1993, Cancer research.

Dysfunction of natural killer activity in a family with chronic fatigue syndrome.

J. Bryant, P. Levine, T. Whiteside, 1998, Clinical immunology and immunopathology.

In vitro cytokine production by normal human peripheral blood mononuclear cells as a measure of immunocompetence or the state of activation.

J. Bryant, T. Whiteside, D. Friberg, 1994, Clinical and diagnostic laboratory immunology.

InVitro Cytokine Production byNormalHumanPeripheral Blood Mononuclear Cells asaMeasureofImmunocompetence ortheState ofActivation

J. Bryant, D. Friberg, 1994 .

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

James N Ingle, E. Winer, T. Powles, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DCIS: evidence from radomized trials

S. Paik, J. Bryant, C. Geyer, 2003 .

Mitoxantrone and 5‐azacytidine for refractory/relapsed ANLL or CML in blast crisis: A leukemia intergroup study

J. Bryant, G. Browman, H. Preisler, 1993, American journal of hematology.

Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.

A. Taghian, J. Bryant, N. Wolmark, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between number of lymph node dissected and the risk of axillary/supraclavicular failure in patients with breast cancer treated by mastectomy and chemotherapy (+/- tamoxifen) without radiation: results from five NSABP trials

A. Taghian, J. Bryant, N. Wolmark, 2002 .

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.

J. Bryant, N. Wolmark, B. Fisher, 2001, Journal of the National Cancer Institute.

Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.

J. Bryant, S. Anderson, Roy E. Smith, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

J. Bryant, D. Wickerham, N. Wolmark, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.

Norman Wolmark, S. Paik, J. Bryant, 2004, Journal of the National Cancer Institute.

Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS. Correlation with serum interleukin-6 levels and organ dysfunction.

J. Bryant, M. Pinsky, T. Whiteside, 1995, JAMA.

Calculation of lytic units for the expression of cell-mediated cytotoxicity.

R. Day, J. Bryant, T. Whiteside, 1992, Journal of immunological methods.

Estrogen, Progesterone and HER2 Receptor Discordance Between Primary Tumor and Brain Metastases in Breast Cancer and Its Effect on Treatment and Survival.

P. Brown, M. Mehta, J. Buatti, 2020, Neuro-oncology.

Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

Jong-Hyeon Jeong, Norman Wolmark, J. Bryant, 2002, The New England journal of medicine.

Generation of activated natural killer (A‐NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl‐positive targets

Steven M. Pincus, J. Bryant, T. Whiteside, 1996, British journal of haematology.

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

M H Gail, R. Croyle, M. Gail, 1999, Journal of the National Cancer Institute.

Multi-gene Rt-pcr assay for predicting recurrence in node negative breast cancer patients-nsabp studies B-20 and B-14

Norman Wolmark, Soonmyung Paik, Gong Tang, 2003 .

Adjuvant therapy for very young women with breast cancer: need for tailored treatments.

R. Gray, R. Gelber, J. Bryant, 2001, Journal of the National Cancer Institute. Monographs.

Pathobiology of preoperative chemotherapy

J. Bryant, N. Wolmark, B. Fisher, 2002 .

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

B Fisher, S. Paik, J. Bryant, 1998, Journal of the National Cancer Institute.

S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen- receptor-positive breast cancer

J. Bryant, J. Costantino, B. Fisher, 2004, Breast Cancer Research and Treatment.

Analysis of Cause-Specific Events in Competing Risks Survival Data

John Bryant, James J. Dignam, H.Sam Wieand, 2003, Advances in Survival Analysis.

Granulocytopenia in Cancer Patients Treated in a Phase I Trial with Recombinant Human Tumor Necrosis Factor

J. Kirkwood, J. Bryant, M. Ernstoff, 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Statistical considerations in assessing molecular markers for cancer prognosis and treatment efficacy.

S. Paik, J. Bryant, J. Dignam, 2002, Methods in molecular biology.

Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer

M. Cronin, S. Paik, G. Tang, 2005 .

Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial

W. Curran, M. Scheier, H. Kuerer, 2019, The Lancet.

Effects of therapy with interferon-alpha on peripheral blood lymphocyte subsets and NK activity in patients with chronic hepatitis C.

D. V. van Thiel, J. Bryant, T. Hassanein, 1994, Clinical immunology and immunopathology.

Incorporating toxicity considerations into the design of two-stage phase II clinical trials.

J. Bryant, J Bryant, R Day, 1995, Biometrics.

Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases from 1985 to Today.

P. Brown, M. Mehta, J. Buatti, 2020, International journal of radiation oncology, biology, physics.

Empirical Bayes Analysis for Systems of Mixed Models with Linked Autocorrelated Random Effects

R. Day, J. Bryant, 1991 .

Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

Greg Yothers, Michael Ewer, Norman Wolmark, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxi fen , Radiat ion Therapy , or Both for Prevent ion of Ips i la tera l Breast Tumor Recurrence Af ter Lumpectomy in Women With Invas ive Breast Cancers of One Cent imeter or Less

S. Paik, J. Bryant, D. Wickerham, 2002 .

Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer.

J. Kirkwood, J. Bryant, S. Agarwala, 2000, Cytokines, cellular & molecular therapy.

Adaptation of bivariate frailty models for prediction, with application to biological markers as prognostic indicators

R. Day, J. Bryant, John Bryant, 1997 .

Semiparametric Models for Cumulative Incidence Functions

James J Dignam, J. Bryant, J. Dignam, 2004, Biometrics.

Centralized medical monitoring in phase III clinical trials: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience

J. Bryant, A. Soran, A. Brown, 2006, Clinical trials.

Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project.

B Fisher, J. Bryant, N. Wolmark, 1998, Controlled clinical trials.

Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05.

J. Bryant, N. Wolmark, J. Grem, 1998, Journal of the National Cancer Institute.

NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: A description of the trial

Donald L. Weaver, Richard M. Single, David N. Krag, 2004, Annals of Surgical Oncology.

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

J. Bryant, M. Lotze, S. Gollin, 1996, The Journal of clinical investigation.

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

J. Bryant, D. Wickerham, H. Bear, 2023, Journal of Clinical Oncology.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

S. Steinberg, E. Rutgers, E. Winer, 2018, The Lancet. Oncology.

Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology Group.

J. Kirkwood, J. Bryant, M. Oken, 1997, Journal of immunotherapy.

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.

J. Bryant, B. Fisher, Jiping Wang, 2001, Journal of the National Cancer Institute. Monographs.

A. Taghian, J. Bryant, N. Wolmark, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early Stopping of Cancer Clinical Trials

J. Bryant, J. Dignam, H. Wieand, 2005 .

Association of tamoxifen and uterine sarcoma.

J. Bryant, J. Costantino, D. Wickerham, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.